Canton Strategic Holdings (CNTN) Interest & Investment Income (2023 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Interest & Investment Income came in at $318178.0 in Q1 2026, up 2268.1% YoY from $13436.0 in Q1 2025, and up 1203.05% on a QoQ basis from $24418.0 in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Interest & Investment Income (2023 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 4 years of Interest & Investment Income data on file, last reported at $318178.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 2268.1% year-over-year to $318178.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $346152.0 (up 106.72% YoY) and the FY2025 annual result came in at $41410.0, down 83.43% from the prior year.
- Interest & Investment Income grew to $318178.0 in Q1 2026, from $24418.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $318178.0 in Q1 2026 to a low of $1388.0 in Q3 2025.
- A 4-year average of $58625.2 and a median of $32248.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2025 — Interest & Investment Income plunged 98.09% — and 2026, when it jumped 2268.1%.
- Tracing CNTN's Interest & Investment Income over 4 years: stood at $57733.0 in 2023, then slumped by 52.07% to $27672.0 in 2024, then dropped by 11.76% to $24418.0 in 2025, then soared by 1203.05% to $318178.0 in 2026.
- The last three Interest & Investment Income figures came in at $318178.0 (Q1 2026), $24418.0 (Q4 2025), and $1388.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 311,848.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 311,848.00 |
| Mar 31, 2026 | 318,178.00 |
| Dec 31, 2025 | 24,418.00 |
| Sep 30, 2025 | 1,388.00 |
| Jun 30, 2025 | 2,168.00 |
| Mar 31, 2025 | 13,436.00 |
| Dec 31, 2024 | 27,672.00 |
| Sep 30, 2024 | 72,728.00 |
| Jun 30, 2024 | 53,614.00 |
| Mar 31, 2024 | 95,894.00 |
| Dec 31, 2023 | 57,733.00 |
| Sep 30, 2023 | 28,451.00 |
| Jun 30, 2023 | 34,199.00 |
| Mar 31, 2023 | 32,248.00 |